Jolynn Tumolo

Multiple sclerosis (MS) is associated with a reduced risk of Alzheimer disease pathology, according to a study published inAnnals of Neurology.

Pandemic’s Effect on Youth Mental Health Varied Across Different Groups

Patients with a particular cognitive biotype of treatment-resistant depression are more likely to experience improvement with transcranial magnetic stimulation (TMS) compared with other patients, according to a study published in Nature Mental Health that was carried out in collaboration with the National Veterans Administration (VA).

DYNE-251 for DMD Yields Promising Biomarker, Functional Results in Early-Stage Trial

Single-Dose Infusion Reduces Migraine Frequency in Phase 2 Trial

Preferred Pharmaceuticals Inc. is recalling 266 bottles of ibuprofen tablets distributed in California and Nevada, according to the September 4, 2024, US Food and Drug Administration (FDA) Enforcement Report. The affected tablets failed to meet impurity/degradation specifications during 18-month stability testing.

Dr Reddy’s Laboratories Inc. is recalling 150 040 bottles of IBU (ibuprofen) tablets because of an unknown impurity. According to the September 4, 2024, US Food and Drug Administration (FDA) Enforcement Report, testing revealed impurity results of 0.13% and 0.11%. The specification limit is 0.10%.

Glenmark Pharmaceuticals Inc. USA is recalling 2404 bottles of indomethacin extended-release capsules distributed throughout the United States by Taro Pharmaceuticals USA, Hawthorne, New York. According to the September 4, 2024, US Food and Drug Administration (FDA) Enforcement Report, samples failed to meet dissolution specifications during testing.

Robust evidence supports the use of upadacitinib for the treatment of patients with axial spondyloarthritis (axSpA), according to a meta-analysis published in the journal Clinical Rheumatology.

An investigational drug for patients with multiple sclerosis (MS) yielded mixed results in a trio of phase 3 trials.